HDAC inhibitor CHR-2845
Term · Oncology and biomedicine · MLC-T-ONC-014062
A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.
| Identifier | MLC-T-ONC-014062 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | histone deacetylase inhibitor CHR-2845 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014062",
"term": "HDAC inhibitor CHR-2845",
"field": "Oncology and biomedicine",
"definition": "A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.",
"synonyms": [
"histone deacetylase inhibitor CHR-2845"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/hdac-inhibitor-chr-2845/"
}
Record 8,291 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.